ENZON PHARMACEUTICALS, INC. financial data

Symbol
ENZN on OTC
Location
Cranford, NJ
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 5065% % -17%
Return On Equity -216% % -546%
Return On Assets -5.3% % -265%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 74,214,603 shares 0%
Common Stock, Shares, Outstanding 74,214,603 shares 0%
Entity Public Float $6,814,434 USD -10%
Common Stock, Value, Issued $742,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 74,215,000 shares 0%
Weighted Average Number of Shares Outstanding, Diluted 74,215,000 shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $26,000 USD
Operating Income (Loss) $4,164,000 USD -242%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $2,124,000 USD -260%
Income Tax Expense (Benefit) $286,000 USD -67%
Net Income (Loss) Attributable to Parent $2,410,000 USD -258%
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $43,256,000 USD -7.2%
Other Assets, Current $411,000 USD 22%
Assets, Current $43,667,000 USD -7%
Deferred Income Tax Assets, Net $26,000 USD -92%
Assets $43,693,000 USD -7.6%
Accounts Payable, Current $331,000 USD 0%
Accrued Liabilities, Current $209,000 USD 95%
Liabilities, Current $540,000 USD 23%
Retained Earnings (Accumulated Deficit) $72,230,000 USD -3.5%
Stockholders' Equity Attributable to Parent $923,000 USD -133%
Liabilities and Equity $43,693,000 USD -7.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $618,000 USD -346%
Net Cash Provided by (Used in) Financing Activities $1,275,000 USD 0%
Common Stock, Shares Authorized 170,000,000 shares 0%
Common Stock, Shares, Issued 74,214,603 shares 0%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,893,000 USD -85%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $43,256,000 USD -7.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities $0 USD
Deferred Tax Assets, Valuation Allowance $32,392,000 USD -4.9%
Deferred Tax Assets, Gross $32,409,000 USD -5.8%
Deferred Income Tax Expense (Benefit) $364,000 USD -68%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2,960,000 shares 0%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) $2,000 USD 0%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%